<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1083">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147051</url>
  </required_header>
  <id_info>
    <org_study_id>RB-II-2020</org_study_id>
    <nct_id>NCT05147051</nct_id>
  </id_info>
  <brief_title>Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of REAMBERIN® (Meglumine Sodium Succinate) Used for Correction of Metabolic Acidosis in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POLYSAN Scientific &amp; Technological Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlant Clinical Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>POLYSAN Scientific &amp; Technological Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several&#xD;
      minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration),&#xD;
      is often observed in critically ill patients with various underlying diseases. Metabolic&#xD;
      acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous,&#xD;
      excretory, hematological, endocrine, musculoskeletal and immune systems and is associated&#xD;
      with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic&#xD;
      acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs&#xD;
      cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate&#xD;
      the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in&#xD;
      critically ill patients with metabolic acidosis and choose the optimal volume of its solution&#xD;
      for the correction of metabolic acidosis in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elimination of acidosis at 24 hours after the start of treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>The proportion of patients who have achieved normalization of the serum bicarbonate level (normalization = serum hydrocarbonate ion concentration ≥22 mmol / Liter), at 24 hours after the start of therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Metabolic Acidosis</condition>
  <arm_group>
    <arm_group_label>Reamberin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine Sodium Succinate</intervention_name>
    <description>500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute</description>
    <arm_group_label>Reamberin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated written Informed Consent (if unconscious due to a critical condition,&#xD;
             the decision is made by a Council consisting of 3 physicians)&#xD;
&#xD;
          2. Male and female patients aged 18-70&#xD;
&#xD;
          3. Critical illness ((shock (including traumatic, hypovolemic), major trauma, acute&#xD;
             massive blood loss, acute complicated surgical diseases of the abdominal organs)&#xD;
             accompanied by metabolic acidosis, defined as serum bicarbonate &lt;22mmol/L&#xD;
&#xD;
          4. pH of arterial blood 7.20-7.35, inclusive&#xD;
&#xD;
          5. Planned volume of infusion &gt;= 1500 ml per day&#xD;
&#xD;
          6. Interval between admission to the ICU and randomization &lt;24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant and lactating women&#xD;
&#xD;
          2. Known hypersensitivity to any component of the study drug / placebo&#xD;
&#xD;
          3. Chronic kidney disease stage C5 (end-stage renal failure)&#xD;
&#xD;
          4. Acute hepatic failure (ALT &gt; 15 upper normal limits) or liver cirrhosis&#xD;
&#xD;
          5. Traumatic brain injury accompanied by cerebral edema&#xD;
&#xD;
          6. Previously diagnosed mental illness&#xD;
&#xD;
          7. Any chronic disease in the terminal stage with a life expectancy of &lt; 3 months&#xD;
&#xD;
          8. HIV infection&#xD;
&#xD;
          9. Clinically significant cardiovascular disease (unstable angina pectoris or angina&#xD;
             pectoris of functional class III or higher; chronic heart failure III - IV class&#xD;
             according to NYHA; acute myocardial infarction within 6 months before screening)&#xD;
&#xD;
         10. Extremely low or extremely high body fat&#xD;
&#xD;
         11. Infusion sodium bicarbonate, sodium bicarbonate, trometamol, Sterofundin, Quintasol,&#xD;
             Ringer's lactate (Hartmann's solution) within 6 hours before screening&#xD;
&#xD;
         12. Acute respiratory acidosis&#xD;
&#xD;
         13. Poisoning with chemical compounds causing metabolic acidosis&#xD;
&#xD;
         14. Alcohol in saliva at screening &gt;= 0.5 pro mille&#xD;
&#xD;
         15. Previously diagnosed chronic obstructive pulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Yu Kirov</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ Arkhangelsk region &quot;First GKB named after E.E. Volosevich&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksey L Kovalenko, Doc Biol Sci</last_name>
    <phone>+7 (812) 710 8225</phone>
    <phone_ext>212</phone_ext>
    <email>science@polysan.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>GBUZ Arkhangelsk region &quot;First GKB named after E.E. Volosevich&quot;</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Yu Kirov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Clinical Hospital</name>
      <address>
        <city>Ivanovo</city>
        <zip>152040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana A Bragina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with a polyclinic of the Office of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renat R Gubaydullin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Privolzhsky District Medical Center</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislav A Bel'skiy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgenij Yu Kovalchuk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Mordovian State University n.a. N.P. Ogarev</name>
      <address>
        <city>Saransk</city>
        <zip>430005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay A Pyataev</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic acidosis</keyword>
  <keyword>critical illness</keyword>
  <keyword>acid-base disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

